InVivo Therapeutics announces first Canadian site for cervical spinal cord injury study

174
Invivo Therapeutics’ Neuro-spinal scaffold

InVivo Therapeutics has received approval from the Toronto Western Hospital’s Research Ethics Board to enrol patients as part of its cervical spinal cord injury study. Toronto Western Hospital is the first study site for the company’s cervical spinal cord injury study.

Michael Fehlings has been named principal investigator at the site. Fehlings is currently director of the Spinal Program, part of Toronto Western Hospital’s Krembil Neuroscience Centre at the University Health Network, Toronto, Canada, professor in the Department of Surgery, director of the University of Toronto Neuroscience Program, co-director of the University of Toronto Spine Program, and Krembil chair in Neural Repair and Regeneration.

Fehlings has published over 725 peer-reviewed articles, principally in the area of spinal cord injury and complex spinal surgery. He is also currently the principal investigator at the site for InVivo’s INSPIRE study, which is studying the Neuro-spinal scaffold in acute, complete (AIS A) thoracic patients.

Fehlings says, “Our centre remains enthusiastic about addressing the unmet need in cervical spinal cord injuries and being part of InVivo’s pioneering efforts in this exciting and promising field.”

The company has also announced the appointment of Christopher McNulty as chief financial officer. He will be taking over for the interim chief financial officer, Melanie Morel-Ferris, CPA, who will remain as the company’s senior director, Finance and controller.